Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 63,400 people in 80 countries and markets its products in around 170 countries. For more information visit novonordisk.com.

This page isn’t intended for discussions about products.  As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to remove those that are off-topic, abusive or intended to spam. 

Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: 
https://www.novonordisk.com/contact-us/find-local-information.html

For other customer complaints, please contact us here: 
https://www.novonordisk.com/contact-us.html

Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. 

Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users.

Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html

Affimed

Xencor

Innate Pharma

IO Biotech

Pieris Pharmaceuticals

Novo Nordisk

Our full-year results are out!

In 2023, we reached more than 40 million people with our diabetes and obesity medicines.
 
Hear our CEO Lars Fruergaard Jørgensen reflect on our performance and learn more about our results and ambitions in our Annual Report here https://lnkd.in/gu4MH2U
 
 
#DrivingChange #FullYearResults #AnnualReport

We're looking forward to the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) 6-9 March! Follow along via Novo Nordisk CongressHub where we'll be highlighting the latest innovations in diabetes care 💙 

https://lnkd.in/g9SWahkq

#ATTD2024 #Diabetes #DiabetesTechnology #Innovation

From small beginnings to groundbreaking innovation - 100 years of #DrivingChange 💙

Learn more about our history of innovation here: https://lnkd.in/dPymS-V5

#NovoNordisk #Heritage #Innovation

How do we contribute to society?
 
Learn more about our commitment to patients, innovation and access to healthcare in our #AnnualReport https://lnkd.in/dxSA_D4V

Inspiring the future of science 💙 
 
From aspiring scientists to our very own colleagues – we’re marking International Day of Women and Girls in Science together.
 
Let’s inspire even more women to a life in science, technology, engineering and math (STEM).
 
Explore our career opportunities here: https://lnkd.in/dfHdaYP
 
#DrivingChange #WomenInScience #STEM

Dr Ulla Hedner - an inspiring pioneer in haemophilia treatment!
 
When Dr Ulla Hedner needed a development partner to produce and test recombinant FVIIa, she turned to us. We were honoured to collaborate on the project in 1985 which has since helped thousands of people living with haemophilia with inhibitors and other rare bleeding disorders.
 
Join us in congratulating her for receiving the 2024 #EAHAD Lifetime Achievement Award for her remarkable contributions to the #haemophilia community in Europe and around the world.
 
#DrivingChange #WomeninScience #Innovation #EAHADCongress

2023 was an extraordinary year of innovation, growth and impact. 
 
Thank you to everyone for #DrivingChange with us!
 
Check out some of our 2023 highlights and learn more in our #AnnualReport here https://lnkd.in/dxSA_D4V

Applications to the Pharmaceutical Medicine Programme (PMP) are now open. This is an exciting opportunity for Medical Doctors with 2-5 years of clinical and/or research experience, to join one of the most successful pharmaceutical companies in the world. Use your medical and scientific expertise to create better treatments and care for people living with serious chronic diseases around the world.

Interested? Find out more about the PMP here: https://brnw.ch/21wGCeB

Pharmaceutical manufacturing has changed dramatically over the last 100 years, making it safer and more efficient than ever before. 

100 years ago, we used manual processes to meet the needs of patients who lived with diabetes in Denmark and in Europe. Today, we produce half of the world’s insulin, and we want to continue to deliver the highest quality of care to patients for generations to come. 

To continue meeting the needs of our millions of patients around the globe, we’re ramping up our production – fast. But scaling at speed demands doing things differently. Thinking outside of the box. To get there, we’re embracing modern technology and bringing the best minds together. This is where you come in! Help us ramp up our production while you ramp up your career!  Visit: https://brnw.ch/21wGpy6

Obesity can have many different causes, and can lead to multiple chronic health issues.

We are #drivingchange to make #obesity a healthcare priority.

Learn more here: https://lnkd.in/eCyWpsQ

Ask Oz

HemaGo

Novo Rocket Trooper

Growth Evaluation Tool

Virtual Joint Bleed

Coags Uncomplicated

Speaker Slides

Domain Not Resolving

Apple Mobile Web Clips Icon

DNSSEC

Google Maps

Amazon

nginx

US Privacy User Signal Mechanism

IPv6

jsDelivr

Google Apps for Business

Co-Founder & Director

Bhavesh Fatania

Managing Assistant General Counsel, Intellectual Property

Chloe Jiang

Executive Vice President & Senior VP, Head of North America Operations and President of NNI

Douglas J. Langa

Legal

Leon Lum

Melissa DeHonney

Vice President

Anders Nørbygaard

VP Sales, Central Area

Brian Krebs

Dan Arnott

Senior VP & Project Assistant

Ditte Bræstrup

Vice President, Pricing, Contract Ops & Reimbursement

Farruq Jafery

Sylvie Gregoire

Marc Newman

Thomas Koestler

Evi Mathiou

Karen Katen

Shamim Rahman

Lars Køppler

Lars Sorensen

President & CEO

Marianne Hedegaard

Service Manager (eDevice/eSolution in Clinical Trials)

Maziar Mike Doustdar

Executive Vice President, International Operations

Maura Reilly

Associate Director

Monique Carter

EVP People & Organisation

Henrik Gürtler

Corporate Vice President of Human Resource Development

Greg Jones

Vice President, Legal Affairs

Christian Wenzel Tornøe

Principal Scientist

IO Biotech is a clinical-stage biotech company developing disruptive immune therapies for the treatment of cancer.

Innate Pharma is a biopharmaceutical company developing immunotherapy drug candidates for the treatment of cancer and inflammatory diseases.

Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.

Xencor develops superior monoclonal antibody therapeutics to treat autoimmune disorders, asthma, allergic diseases and cancer.

Female Founded Investors active in Greater Boston Area

Europe Companies With More Than $50M in Revenue (Top 10K)

Medical Public Companies With More Than $100M in Revenue

Medical Public Companies With More Than $1B in Revenue

Novo Nordisk is a healthcare company that produces and distributes insulin and other diabetes drugs to treat chronic diseases. Its main offerings include pioneering scientific breakthroughs and expanding access to their medicines, with the ultimate goal of preventing and curing disease.

Post-IPO Equity - Novo Nordisk

Bagsværd

Hovedstaden

Denmark

Europe

News Highlights: Top Company News of the Day - Tuesday at 11 PM ET

News Highlights: Top Company News of the Day - Wednesday at 5 AM ET

News Highlights: Top Company News of the Day - Wednesday at 1 AM ET

Biden floats more Medicare, Medicaid coverage of obesity drugs

Novo Nordisk A/S - share repurchase programme

NanoVation Bolsters Board, Captures Capital to Advance Novel Biotech

Weight-loss drug coverage rises among largest US employers, Mercer survey finds

Endocrinology Drugs Market Analysis by Therapy Area, Distribution Channel and Region - A Forecasted $53.85 Billion Industry by 2030

Weight loss drug makers still have huge upside, and the market overreacted to RFK Jr. named to top health role, BMO says

Medications designed to manage blood sugar levels in individuals with type 2 diabetes by mimicking the incretin hormones that the body usually produces to stimulate insulin release.

Pharmaceutical solutions aimed at assisting weight management and reducing obesity-related health risks.

A treatment for haemophilia A that reduces bleeding episodes, administered either weekly or monthly.

A recycling program for used medical devices, particularly injection pens, to reduce plastic waste and promote sustainability.

United States

North America

Germany

United Kingdom

India

Asia

HTML5

Google Maps API

Valimail

Google Drive

Google Tag Manager

Facebook Comments

DigiCert

Apache Server

Google Fonts

Modernizr

Eli Lilly and Company is a global pharmaceutical company that develops and markets a range of pharmaceutical products.

Eli Lilly and Co

AstraZeneca is a multinational pharmaceutical and biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines.

AstraZeneca

Abbott is a global healthcare company that develops and manufactures medical devices, diagnostics, branded generic pharmaceuticals, and nutritional products.

Abbott

Bristol-Myers Squibb Company is a global biopharmaceutical company that focuses on discovering, developing, and delivering innovative medicines for patients with serious diseases.

Bristol-Myers Squibb Co

Sanofi is a global pharmaceutical company that researches, develops, and manufactures pharmaceutical products for various therapeutic areas.

Sanofi-aventis Groupe

Novo Nordisk is a Danish multinational pharmaceutical company that is dedicated to driving change to defeat serious chronic diseases, particularly diabetes. The company applies its core capabilities to pioneer the discovery and development of innovative medicines and aims to lead in all the therapy areas in which it is present, with the ultimate aspiration to prevent and cure disease.

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

news impact assignment basic	general	Mar 7, 2024 3:58 PM	34c30db6
public peers	general
news daily refresh	general	Dec 4, 2024 2:16 PM	63b93cee
news processing daily refresh	general	May 21, 2024 3:10 AM	db0f87c2
news impact assignment daily	general	May 21, 2024 3:54 PM	ca516824
news processing basic	general	Mar 7, 2024 3:58 PM	597f9d9c
company summary	general
signals	general	Mar 7, 2024 3:58 PM	68c43cdf
crunchbase trigger	general	Nov 27, 2024 12:50 PM	d2d9e65f
crunchbase profile	general	Nov 27, 2024 1:24 PM	be2a2a51
li profile	general	Mar 7, 2024 3:58 PM	3fc7cc27
translate crunchbase fundingrounds	general	Nov 27, 2024 2:00 PM	88c98ceb
peers	general	Mar 7, 2024 3:58 PM	0b42c759
news basic	general	Dec 4, 2024 2:13 PM	a320be4f
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:NOVONORDISK

Novo Nordisk A/S

Last Close

102.63

22/11 21:00

Market Cap

628.74B

Beta: -

Volume Today

7.75K

Avg: -